AU2013202768B2 - Treatment of cancer with TOR kinase inhibitors - Google Patents

Treatment of cancer with TOR kinase inhibitors Download PDF

Info

Publication number
AU2013202768B2
AU2013202768B2 AU2013202768A AU2013202768A AU2013202768B2 AU 2013202768 B2 AU2013202768 B2 AU 2013202768B2 AU 2013202768 A AU2013202768 A AU 2013202768A AU 2013202768 A AU2013202768 A AU 2013202768A AU 2013202768 B2 AU2013202768 B2 AU 2013202768B2
Authority
AU
Australia
Prior art keywords
substituted
pyrazin
unsubstituted
tor kinase
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013202768A
Other languages
English (en)
Other versions
AU2013202768A1 (en
Inventor
Kimberly Elizabeth Fultz
Kristen Mae Hege
Deborah Mortensen
Rama K. Narla
Heather Raymon
Toshiya Tsuji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signal Pharmaceuticals LLC
Original Assignee
Signal Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharmaceuticals LLC filed Critical Signal Pharmaceuticals LLC
Publication of AU2013202768A1 publication Critical patent/AU2013202768A1/en
Priority to AU2015213397A priority Critical patent/AU2015213397B2/en
Application granted granted Critical
Publication of AU2013202768B2 publication Critical patent/AU2013202768B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013202768A 2012-10-18 2013-04-06 Treatment of cancer with TOR kinase inhibitors Active AU2013202768B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2015213397A AU2015213397B2 (en) 2012-10-18 2015-08-14 Treatment of cancer with TOR kinase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261715510P 2012-10-18 2012-10-18
US61/715,510 2012-10-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015213397A Division AU2015213397B2 (en) 2012-10-18 2015-08-14 Treatment of cancer with TOR kinase inhibitors

Publications (2)

Publication Number Publication Date
AU2013202768A1 AU2013202768A1 (en) 2014-05-08
AU2013202768B2 true AU2013202768B2 (en) 2015-11-05

Family

ID=50023830

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013202768A Active AU2013202768B2 (en) 2012-10-18 2013-04-06 Treatment of cancer with TOR kinase inhibitors

Country Status (19)

Country Link
US (1) US20140113904A1 (enExample)
EP (1) EP2908814B1 (enExample)
JP (3) JP2015534981A (enExample)
KR (2) KR102157914B1 (enExample)
CN (2) CN105050601A (enExample)
AU (1) AU2013202768B2 (enExample)
BR (1) BR112015008834A2 (enExample)
CA (1) CA2888609C (enExample)
EA (1) EA029164B1 (enExample)
ES (1) ES2777936T3 (enExample)
IL (1) IL238326B (enExample)
MX (1) MX368407B (enExample)
MY (1) MY176599A (enExample)
NI (1) NI201500055A (enExample)
PH (2) PH12020550858A1 (enExample)
SG (2) SG11201502999YA (enExample)
UA (1) UA117000C2 (enExample)
WO (1) WO2014062878A2 (enExample)
ZA (1) ZA201503105B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
SG11201505446WA (en) 2013-01-16 2015-08-28 Signal Pharm Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
EP3131552B1 (en) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
WO2016010886A1 (en) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
CN114702495A (zh) 2015-11-20 2022-07-05 福马治疗有限公司 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection
CN110403943B (zh) * 2019-08-19 2022-05-17 陕西科技大学 Cc-115在制备抗真菌药物中的应用及其药物组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010044893A1 (en) * 2008-10-17 2010-04-22 Merck & Co. Combination therapy
WO2011053518A1 (en) * 2009-10-26 2011-05-05 Signal Pharmaceuticals, Llc Methods of synthesis and purification of heteroaryl compounds
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
US20120238562A1 (en) * 2011-03-09 2012-09-20 Cedars-Sinai Medical Center Treatment of cancer by targeting molecules that influence mst1/stk4 signaling

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1159582C (zh) * 2001-12-08 2004-07-28 云南大学 一种人体全血或血清总前列腺特征性抗原值，总前列腺特征性抗原灰区值检测方法
GB0509748D0 (en) 2005-05-13 2005-06-22 Univ Glasgow Materials and methods relating to cell based therapies
US20070238745A1 (en) * 2006-04-07 2007-10-11 University Of South Florida PI3K-Akt Pathway Inhibitors
ES2627352T3 (es) * 2006-10-19 2017-07-27 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas
RU2474582C2 (ru) 2006-10-19 2013-02-10 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Гетероарильные соединения, их композиции и их применение в качестве ингибиторов протеинкиназы

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010044893A1 (en) * 2008-10-17 2010-04-22 Merck & Co. Combination therapy
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
WO2011053518A1 (en) * 2009-10-26 2011-05-05 Signal Pharmaceuticals, Llc Methods of synthesis and purification of heteroaryl compounds
US20120238562A1 (en) * 2011-03-09 2012-09-20 Cedars-Sinai Medical Center Treatment of cancer by targeting molecules that influence mst1/stk4 signaling

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BERK L, et al. Cancer Chemother Pharmacol, (published online 10 January 2012), Vol 69, pp 1369-1377. *
ELLIS L, et al. PLOS One (2011), Vol 6 Issue 11, e27178, pp1-14. *
GRAVINA GL. Endocrine- Related Cancer, (2011), Vol 18, pp 385-400. *
MORGAN TM, et al. Curr Cancer Drug Targets, (2009) Vol 9 No 2, pp 237-249. *
PULUKURI SM et al. The Journal of Biological Chemistry, (2005) Vol 280 No 43, pp 36529-36540. *
'Ridaforolimus,' Adis R&D Profile; Drugs RD, (2010) Vol 10(3), pp 165-178. (No Author Listed). *

Also Published As

Publication number Publication date
MX368407B (es) 2019-10-02
KR20200108923A (ko) 2020-09-21
NI201500055A (es) 2015-09-10
WO2014062878A3 (en) 2014-06-26
CN105050601A (zh) 2015-11-11
JP2019081771A (ja) 2019-05-30
JP2021050213A (ja) 2021-04-01
ES2777936T3 (es) 2020-08-06
EA029164B1 (ru) 2018-02-28
UA117000C2 (uk) 2018-06-11
AU2013202768A1 (en) 2014-05-08
EA201590744A1 (ru) 2015-11-30
CA2888609C (en) 2020-12-01
BR112015008834A2 (pt) 2017-07-04
PH12015500867A1 (en) 2015-06-22
MY176599A (en) 2020-08-18
JP7162543B2 (ja) 2022-10-28
WO2014062878A2 (en) 2014-04-24
PH12015500867B1 (en) 2015-06-22
MX2015004874A (es) 2015-08-05
CN110721186A (zh) 2020-01-24
KR20150070319A (ko) 2015-06-24
SG11201502999YA (en) 2015-05-28
KR102267927B1 (ko) 2021-06-21
IL238326A0 (en) 2015-06-30
PH12020550858A1 (en) 2023-02-20
WO2014062878A9 (en) 2014-12-18
US20140113904A1 (en) 2014-04-24
SG10201810575WA (en) 2019-01-30
CA2888609A1 (en) 2014-04-24
EP2908814B1 (en) 2019-12-25
EP2908814A2 (en) 2015-08-26
JP2015534981A (ja) 2015-12-07
IL238326B (en) 2018-03-29
ZA201503105B (en) 2016-11-30
KR102157914B1 (ko) 2020-09-18

Similar Documents

Publication Publication Date Title
AU2011212927B2 (en) Identification of LKB1 mutation as a predictive biomarker for sensitivity to TOR kinase inhibitors
EP2825168B1 (en) Treatment of cancer with tor kinase inhibitors
EP2825171B1 (en) Treatment of cancer with tor kinase inhibitors
JP7162543B2 (ja) Ｔｏｒキナーゼ阻害剤を用いた癌の治療
AU2013203153A1 (en) Treatment of cancer with TOR kinase inhibitors
AU2013203714A1 (en) Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
AU2015213397B2 (en) Treatment of cancer with TOR kinase inhibitors
HK40013177A (en) Treatment of prostate cancer with tor kinase inhibitors
HK1201755B (en) Treatment of cancer with tor kinase inhibitors
HK1202247B (en) Treatment of cancer with tor kinase inhibitors
AU2015213400A1 (en) Treatment of cancer with TOR kinase inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)